Belite Bio, IncBLTE

NASDAQHealthcareBiotechnology$164.11-3.21%

Focused on developing treatments for retinal degenerative diseases, the company is a clinical‑stage biopharmaceutical developer advancing small‑molecule therapies that target vitamin A transport pathways. Its lead candidate, tinlarebant, is being studied for conditions such as Stargardt disease and ...

Market Cap: $6.5B52W Range: $49.00 – $200.00

Congressional Interest in Belite Bio, Inc (BLTE)

No congressional trades have been disclosed for Belite Bio, Inc (BLTE) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.

Total Disclosures

Unique Politicians

Buys

Sells

Who in Congress Is Trading BLTE?

No congressional trades found for this stock.

All stocks traded by Congress Full trade feed Most active traders About the STOCK Act Report missing trade

Belite Bio, IncBLTE

Congressional Interest in Belite Bio, Inc (BLTE)

Who in Congress Is Trading BLTE?

Related